IGC shareholders approve director election, ratify auditor, and authorize 3.5M share equity grant

IGC Pharma, Inc.

Richard Prins elected as Class B director, term through 2024 annual meeting.
Manohar Chowdhry & Associates ratified as independent auditor for fiscal 2022.
Board authorized grant of up to 3,500,000 common shares to employees, advisors, directors, and consultants.
Meeting turnout: 37,257,143 shares voted (≈73% of outstanding); 21,876,265 broker non-votes.
All four proposals passed; adjournment proposal was unnecessary.

item 5.02 item 5.07 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Richard Prins

Class B director

IGC · IGC Pharma, Inc.

Effective: 2021-10-15
Filed: October 15, 2021, 7:59 PM ET

On October 15, 2021, Richard Prins was elected to India Globalization Capital’s (the “Company”) Board of Directors at the Annual Meeting, to serve as a Class B director

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Richard Prins was elected as Class B director at IGC Pharma, Inc..

Action: elected
Role: Class B director

Exact text from the filing

On October 15, 2021, Richard Prins was elected to India Globalization Capital’s (the “Company”) Board of Directors at the Annual Meeting, to serve as a Class B director

View on SEC.gov

IGC Pharma, Inc. filing history →

Source: SEC EDGAR

accession 0001185185-21-001484

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.